Annexure 12B Cohort Event Monitoring (CEM) - Treatment Review Form

To be filled at per schedule and when any adverse event reported by the patient on newer drug containing regimen and for the other DR-TB patients when serious adverse event (DAIDS grade 3 or 4) is reported

PATIENT DETAILS	Interview	Date:(DD,	/MM/YYYY)
Patient Name	Age: PMDT	No./ File No:	Nikshay ID:
		Weight (kg):	Sex: □ Male
Patient Address:		Height (cm):	☐ Female
			☐ Others
MEDICAL DETAILS			
Type of TB		Type of drug resistance	
□ Pulmonary TB		☐ H mono/ poly	RR/MDR-TB + any FQ/SLI
☐ Extra-pulmonary TB site/s:	s No Unknown	□ RR/MDR-TB	□ XDR-TB
Pregnancy	Date of LMP: DD/MM/	YYYY or estimated current	gestation (weeks):
status (UPT)	If PREGNANT record par		gestation (weeks).
Breastfeeding an infant	☐ Yes ☐ No ☐ Unknown		
ADR description: Reporter's Narrative (I			as of ADR).
HADN description: Reporter's Narrative (i	Describe the course of ev	rents, tirning and suspected causi	es of ADR):
ADR Terminology/Adverse event			
For patient under CAP during follow up vis	it (Fill the details of any	event happened since the last fol	llow up visit)
(eg. Minor ADR, Accident, Travel, other m	edication etc)		
DAIDS and the ATiples are a sixty of	1		
DAIDS grading (Tick appropriate checkbox			
GRADE 1: Mild symptoms causing no or minim			
GRADE 2: Moderate symptoms causing greate	r than minimal interference v	vith usual social & functional activities v	vith intervention indicated
GRADE 3: Severe symptoms causing inability to	o perform usual social and fur	nctional activities with intervention or h	ospitalization indicated
GRADE 4: Potentially life threatening symptom	ns causing inability to perform	basic self-care functions with intervent	tions indicated to prevent
permanent impairment, persistent di	sability or death		
<u> </u>			

Date of Onset	DD/MM/YY											
Date Resolved					DD/N	лм/ү	Υ					
ADR/SAE Seriousness	□ Death □ Life threatening □ Hospitalization required □ Permanent disability □ Congenital anomaly/ birth defect □ Other medically important condition □ Required intervention to prevent permanent impairment/ damage											
Outcome	Recovered/resolved Recovered/resolved with sequel Recovery date Fatal Recovering/resolving Not recovering/ not resolved Unknown											
For Death/SAE	Date of Death Primary cause of death (if known):											
Causality/Relation to medicine	Assign Causality v H R E Z Km Am Cm Lfx Mfx Cs Eto PAS Lzd Cfz Amx-Clv Clr Bdq Dlm	vith follov Certai		grading for sus	Possible	e [Doubtful or Unlikely	Condition		Unassessable		
Suspected drugs name	·	<u> </u>			·		·					
Dechallenge	No Dechallenge Reaction Abated Dose Reduced Result unknown			Reaction Abated Dose Reduced			Reaction Abated Dose Reduced		No Dechallenge Reaction Abated Dose Reduced Result unknown			
Rechallenge	No Rechallenge Recurrence of event No recurrence Result unknown			Recurrence of event No recurrence			Recurrence of event No recurrence		No Rechallenge Recurrence of event No recurrence Result unknown			
Expectedness	Expected Unexpected	l	Expected Unexpected		Expected Unexpected		Expected Unexpected					

1	Start Date of newer drug Stop Date of newer drug								
l									
If newer drugs (Bdq or	☐Dose Adjusted								
Dlm) is suspected	Temporary Stop								
	Permanent Stop								
☐ Bdq ☐ Dlm	If permanent stop,								
	it was provider decision please specify reason or								
	it was patient decision please specify reason)								
	Batch/Lot No/ Expiry DoseFrequency Route								

Test	Date	Result (units)	Test	Date	Result (units)
Sputum smear			ALT (SGPT)		
Sputum Culture			AST (SGOT)		
Line probe assay			Lactic acid		
Nucleic acid					
testing			Lipase		
Tuberculin Test			Chest X-Ray		Cavities (Y/N) PI specify Xray
					findings
HIV Antibody			ECG		QTc
					Any other changes
CD4 Count			Audiometry		
ESR			Visual acuity		
			Bilirubin- Direct		
Total WBC			-Indirect		
Haemoglobin			Hepatitis markers		
Creatinine			TSH		
Creatinine				1	
Clearance			Other		
Glucose					
Drug susceptibility				1	

Medicines								
Anti-TB medicines	Dosage		Route (Oral/IV/IM					
taken since	(μg/mg/	(OD/BD/	/Topical/			If No.	Reason (s) for	
last interview	g/ml)	TID)	other)	Start Date	Continues	Stop date	stopping #	Action**
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			
					Yes/ No			

Other medicines & traditional medicines taken since last interview	Indication	Dosage (μg/mg/ g/ml)	Frequency (OD/BD/ TID)	Route (Oral/IV/IM /Topical/ other)	Start Date	Continues Yes/ No Yes/ No Yes/ No Yes/ No	Stop date		Reason (s) for stopping#	Action**
All NEW medicines (anti-TB & other) prescribed at this interview	Indication	Dosage (μg/mg/ g/ml)	Frequency (OD/BD/ TID)	Route (Oral/IV/IM /Topical/ other)		Yes/ No	Ex	фес	ited Stop date	Indication
A 4 h		-1::1:-								
Any other re	levant	ciinicai ii	ntormati	on						
REPORTERS	NFORI	MATION								
Name of the	Report	ter:								
Signature:										
Date:										

Dose not changed

Drug withdrawn

Not applicable

Dose reduced

Drug interrupted

 $[\]ensuremath{^{**}}$ Action taken by clinician in case of suspected adverse event linked to a drug